UnitedHealthcare Names 3 Biosimilars Preferred Treatments in 2019 MA Plans
When CMS announced in August 2018 its policy change to allow Medicare Advantage (MA) plans to utilize step therapy as a way to negotiate drug prices, UnitedHealthcare, the nation’s largest MA carrier, publicly celebrated the decision. This week, the insurer rolled out some of the changes it will be implementing in its MA plans as of January 1, 2019.
Read the full article on The Center for Biosimilars here.